LOTTE BIOLOGICS Expands Global Reach,
Showcasing CDMO Prowess in US, Asia, and Europe

■ Strengthening Global CDMO Presence through Consecutive Conference Participation at China Bio, BPI, and CPhI
■ Anticipates Market Share Expansion through Global Partnerships

LOTTE BIOLOGICS, led by CEO Richard Lee, is actively pursuing global order acquisition initiatives by participating in a series of international conferences held throughout the US, Asia, and Europe in the second half of this year. These events will serve as platforms to showcase the company's differentiated competitive edge in the CDMO industry.

After making its debut at the Bio International Convention (BIO USA) in 2022, LOTTE BIOLOGICS has continued to actively participate, hosting a booth at the conference for three consecutive years. LOTTE BIOLOGICS plans to continue this momentum by attending a total of six conferences held worldwide during the latter half of this year.

China Bio Partnering Forum 2024 (China Bio) has been the largest biotech industry conference in China since 2009, and is a major event for establishing global corporate partnerships. The conference, held in Shanghai, China from September 10 to 11, offered opportunities for active global networking through a pre-arranged meeting scheduling program.

BioProcess International 2024 (BPI) will take place in Boston, USA, over four days, from September 23 to 26. This event provides a space for knowledge sharing and partnership discussions across all aspects of biopharmaceutical development and production technologies. With over 250 participating companies, BPI annually attracts more than 3,200 global bio professionals and executives from over 40 countries. This year, the conference will feature nine sessions focusing on enhancing efficiency at each stage of biopharmaceutical development and production, covering topics such as cell line development, cell culture, and manufacturing strategies.

LOTTE BIOLOGICS plans to establish global partnerships by setting up promotional booths at both events, showcasing the capabilities of the Songdo Bio Campus and the antibody-drug conjugate (ADC) services and manufacturing of the Syracuse Bio Campus in New York.

Additionally, LOTTE BIOLOGICS will promote its position as a global CDMO by participating in other major global conferences, including Bio Europe 2024, Bio Japan 2024, CPhI 2024, and the Biomanufacturing World Summit (BMWS) 2024. Notably, the company plans to strengthen business partnerships with Asian companies and discover potential business opportunities by attending biotech conferences in the Asian region.

A representative from LOTTE BIOLOGICS stated, “We plan to hold in-depth business meetings with potential clients through participation at a diverse range of conferences and booth operations, promoting our differentiated technological capabilities and actively discussing orders for the contract manufacturing of antibody medicines and ADC treatments.”

Newsroom

LOTTE BIOLOGICS participates in 'BIO Japan 2024'